A sequencing and typing kit for MHCII CDS gene

By adopting the same PCR program and gradient cooling and annealing system in MHCII CDS gene detection kit, the problem of insufficient detection accuracy and specificity in the prior art is solved, and efficient and low-cost gene sequencing and typing is achieved, which is suitable for Gene amplification of various HLA subtypes.

CN112553314BActive Publication Date: 2024-11-19NANJING UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202011636047.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-12-31
Publication Date
2024-11-19
Estimated Expiration
2040-12-31

AI Technical Summary

Technical Problem

The prior art has insufficient accuracy and specificity when detecting MHCII CDS genes, and is complex in operation and high cost. Especially when large sequence measurements occur, there are problems such as long time and inaccurate results.

Method used

A sequencing and typing kit for MHCII CDS gene is provided, and the same PCR program is used to amplify genes such as HLA-DRA, HLA-DRB1, HLA-DRB345, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, etc. are used. Gradient cooling annealing system, combined with specific primer combinations, simplifies operation and improves detection efficiency.

Benefits of technology

Based on first-generation sequencing, it realizes high accuracy and strong specificity detection, reduces detection cost, is suitable for gene amplification of different HLA subtypes, has good band specificity and is simple and fast operation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112553314B_ABST
    Figure CN112553314B_ABST
Patent Text Reader

Abstract

The invention discloses a sequencing typing kit for MHCII CDS gene, comprising: PCR buffer, dNTPs, Taq enzyme and primers; the primers consist of a first or second upstream primer group and a downstream primer group; the sequence of the first upstream primer group is shown in SEQ ID NO.1-7; the second upstream primer group is shown in SEQ ID NO.15-22; the sequence of the downstream primer group is shown in SEQ ID NO.8-14. The kit has strong specificity, high sensitivity and simple and quick operation, greatly reduces the detection cost and has broad application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of gene detection, and in particular to a sequencing typing kit for MHCII CDS gene. Background Art

[0002] HLA genes are important proteins that are deeply involved in human major histocompatibility complex and immune-related diseases. Among them, MHCII CDS is mainly expressed in cells in the immune system and has a strong correlation with tissue compatibility in organ transplantation. Therefore, accurate determination of MHCII CDS alleles is very important clinically. However, the above-mentioned MHCII CDS gene is a region with rich polymorphism in the human genome, with a large number of alleles.

[0003] In the prior art, when first-generation sequencing detects MHCII CDS genes, only one band can be measured at a time. When testing multiple bands, the PCR amplification program needs to be reset, otherwise two different light signals will be detected at the same position, causing image confusion. For the determination of large sequences, it has the disadvantages of long time and high cost, but its results are relatively accurate. Compared with first-generation sequencing, second-generation sequencing has the advantages of high throughput and short time, but its accuracy is poor and the read length is short, which restricts the development of PCR detection.

[0004] Therefore, it is necessary to provide a detection product and a detection method that have the advantages of high accuracy, strong specificity, simple and quick operation, etc. Summary of the invention

[0005] In order to solve the above problems existing in the prior art, the present invention provides a sequencing typing kit for MHCII CDS gene with high accuracy and simple operation based on first-generation sequencing, which is achieved by the following technical solutions:

[0006] A sequencing typing kit for MHCII CDS gene includes: PCR buffer, dNTPs, Taq enzyme and amplification primers;

[0007] The amplification primers consist of a first or second upstream primer set and a downstream primer set;

[0008] The sequence of the first upstream primer set is shown in SEQ ID NO.1-7; the sequence of the second upstream primer set is shown in SEQ ID NO.15-22; the sequence of the downstream primer set is shown in SEQ ID NO.8-14;

[0009] The PCR buffer is selected from Tris base, KCl and MgCl 2 One of them.

[0010] Furthermore, the primers for amplifying the DRA gene are a combination of SEQ ID NO.1 or NO.19 and SEQ ID NO.8.

[0011] Furthermore, the primers for amplifying the DRB1 gene are a combination of SEQ ID NO.2, NO.20 or NO.21 and SEQ ID NO.9.

[0012] Furthermore, the primers for amplifying the DRB345 gene are a combination of SEQ ID NO.3 or NO.22 and SEQ ID NO.10.

[0013] Furthermore, the primers for amplifying the DPA1 gene are a combination of SEQ ID NO.4 or NO.15 and SEQ ID NO.11.

[0014] Furthermore, the primers for amplifying the DPB1 gene are a combination of SEQ ID NO.5 or NO.16 and SEQ ID NO.12.

[0015] Furthermore, the primers for amplifying the DQA1 gene are a combination of SEQ ID NO.6 or NO.17 and SEQ ID NO.13.

[0016] Furthermore, the primers for amplifying the DQB1 gene are a combination of SEQ ID NO.7 or NO.18 and SEQ ID NO.14.

[0017] Furthermore, the method for using the kit comprises the following steps:

[0018] 1) Extract sample cDNA;

[0019] 2) performing PCR amplification on the cDNA;

[0020] 3) Connect the amplified product to T vector and sequence it.

[0021] Furthermore, the amplification procedure of step 2) includes: pre-denaturation at 95°C for 3 min, denaturation at 92°C / 95°C for 15 sec, annealing at 48-58°C for 15 sec, extension at 72°C for 60 sec and complete extension at 72°C for 5 min.

[0022] Furthermore, the denaturation, annealing and extension are performed sequentially once as one cycle, and the number of cycles is 4;

[0023] The denaturation condition of the first cycle is 92°C;

[0024] The annealing operations of the first to third cycles were repeated 3 times, and the annealing operation of the fourth cycle was repeated 25 times.

[0025] Furthermore, the annealing temperature for amplifying HLA-DRA, HLA-DRB1, HLA-DRB345, HLA-DPA1, HLA-DPB1 and HLA-DQA1 starts from 58°C and decreases in units of 2°C in the cycle.

[0026] Furthermore, the annealing regime for amplifying HLA-DQB1 was to start from 54°C and decrease in units of 2°C during the cycle.

[0027] Compared with the closest prior art, the technical solution provided by the present invention has the following excellent effects:

[0028] (1) The technical solution provided by the present invention can directly call out MHCII (HLA-DRA, HLA-DRB1, HLA-DRB345, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1) CDS genes from human cDNA using the same PCR procedure on the basis of first-generation sequencing. The kit provided by the present invention has strong specificity, high sensitivity and simple and quick operation, which greatly reduces the detection cost;

[0029] (2) The technical solution provided by the present invention introduces a gradient cooling annealing system in the PCR program, which is suitable for primer Tm values ​​of different primer pairs. Therefore, the HLA CDS genes of different HLA subtypes can be amplified simultaneously using the same program, and the band specificity is good. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 The nucleic acid gel image of the PCR product of Example 1 provided by the present invention;

[0031] Figure 2 The nucleic acid gel image of the PCR product of Example 2 provided by the present invention;

[0032] Figure 3 The nucleic acid gel image of the PCR product of Example 3 provided by the present invention;

[0033] Figure 4 The nucleic acid gel image of the PCR product of Example 4 provided by the present invention;

[0034] Figure 5 The nucleic acid gel image of the PCR product of Example 5 provided by the present invention;

[0035] Figure 6 The nucleic acid gel image of the PCR product of Example 6 provided by the present invention. DETAILED DESCRIPTION

[0036] The technical solutions in the embodiments of the present invention are described clearly and completely below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, but not all of them.

[0037] The sequencing typing kit of MHCII CDS gene provided by the present invention comprises: PCR buffer, dNTPs, Taq enzyme, upstream primer and downstream primer;

[0038] The PCR buffer is selected from Tris base, KCl and MgCl 2 One of them.

[0039] The sequences of the first upstream primer set and the downstream primer set designed by the present invention are shown in Table 1, and the second upstream primer set is shown in Table 2. The difference between the second upstream primer set and the first upstream primer set is that the HLA-DRA, HLA-DRB1, DRB345, HLA-DPA1, HLA-DPB1, HLA-DQA1, and HLA-DQB1 amplified by the second upstream primer set do not contain a signal peptide, and the downstream primers are the same. Using the primer set provided by the present invention, the full exon gene sequence of HLA-DRA, HLA-DRB1, HLA-DRB345, HLA-DPA1, HLA-DPB1, HLA-DQA1, and HLA-DQB1 in a human genome can be amplified using the following same PCR amplification procedure.

[0040] Table 1. First upstream primer set and downstream primers

[0041] type SEQ ID Upstream primer SEQ ID Downstream primer DRA NO.1 ATGGCCATAAGTGGAGTCCC No.8 TTACAGAGGCCCCCTGCGTTC DRB1 No.2 ATGGTGTGTCTGARGCTCCC No.9 TCAGCTCAGGAATCCTSTTGG DRB345 No.3 ATGGTGTGTCTGAAGCTCCC No.10 TCAGCTCAGGARTCCTGTTGG DPA1 NO.4 ATGCGCCCWGAAGACAGAATG No.11 TCACAGGGKCCCCTGGGCCC DPB1 NO.5 ATGATGGTTCTGCAGGTTTCTG No.12 TTATGCAGATCCTCGYTGAAC DQA1 No.6 ATGATCCTAAACAAAGCTCTG No.13 TCACAAKGGCCCTTGGTGTC DQB1 No.7 ATGTCTTGGAARAAGKCTTTGC No.14 TCAGTGCAGRAGCCCTTTC

[0042] Table 2. Second upstream primer set

[0043] type SEQ ID Upstream primer DPA1 No.15 GCTGGGGCCATCAAGGCGGACCAT DPB1 No.16 AGGGCCACTCCAGAGAATTAC DQA1 No.17 GAAGRCATTGTGGCTGACCA DQB1 No.18 AGAGACYCTCCCGAGGATTTCGTG DRA No.19 ATCAAAGAAGAACATGTGATCATC DRB1 No.20 GGGGACACCCRACCACGTTTC DRB1 No.21 GGGGACACCMGACCACGTTTC DRB345 No.22 GGGGACACCCRACCACGTTTCTTG

[0044] Example 1

[0045] The primers of the kit of this embodiment are selected as the first upstream primer set and the downstream primer set shown in Table 1, and the method of using the primers comprises the following steps:

[0046] 1) Extract sample cDNA;

[0047] 2) performing PCR amplification on the cDNA;

[0048] 3) Connect the amplified product to T vector and sequence it.

[0049] The amplification procedure of step 2) is shown in Tables 3-4. The PCR amplification conditions shown in Table 3 are used to amplify the full exon gene sequences of HLA-DRA, HLA-DRB1, DRB345, HLA-DPA1, HLA-DPB1, and HLA-DQA1; the PCR amplification conditions shown in Table 4 are used to amplify the full exon gene sequence of HLA-DQB1.

[0050] Table 3. PCR amplification conditions for HLA-DQA1, HLA-DR, HLA-DRB, HLA-DPA1, and HLA-DPB1

[0051] Cycle steps Temperature / ℃ time Number of cycles Pre-denaturation 95 3min 1 transsexual 92 15sec 1 annealing 58 15sec 3 extend 72 60sec 1 transsexual 95 15sec 1 annealing 56 15sec 3 extend 72 60sec 1 transsexual 95 15sec 1 annealing 54 15sec 3 extend 72 60sec 1 transsexual 95 15sec 1 annealing 52 15sec 25 extend 72 60sec 1 Complete extension 72 5min 1

[0052] Table 4. PCR conditions for amplification of HLA-DQB1

[0053]

[0054]

[0055] like Figure 1 As shown, in this example, the fragments recovered from the gel were connected to the T vector and then sequenced and typed to obtain the genotype of this person: DRA*01:01:01:12, DRB1*09:01:02:04, DRB3*02:02:01:13, DPA1*01:14, DPA1*03:01:01:06, DPB1:05:01:01:12, DPB1:135:01, DQA1:03:02:01:02, DQA1:03:03:01:13, DQB1*02:01:08, DQB1*03:01:01:24.

[0056] Example 2

[0057] The primers of the kit of this embodiment are selected as the first upstream primer set and the downstream primer set shown in Table 1. The human cDNA gene sample provided in this embodiment is detected using the method of Example 1. The nucleic acid gel image is as follows: Figure 2 As shown, in this example, the fragments recovered from the gel were connected to the T vector and then sequenced and typed to obtain the genotype of this person: DPA1*01:03:01:35, DPA1*02:02:02:08, DPB1*05:01:01:10, DPB1*17:01:01:02, DQA1*06:01:01:04, DQA1*05:06:01:02, DQB1:03:98, DQB1*06:09:01:02, DRA*01:01:01:09, DRB1*12:02:01:06, DRB1*11:01:01:04.

[0058] Example 3

[0059] The primers of the kit of this embodiment are selected as the downstream primer set shown in Table 1 and the second upstream primer set shown in Table 2. The human cDNA gene sample provided in this embodiment is detected using the method of Example 1. The nucleic acid gel image is as follows: Figure 3 As shown, in this example, the fragments recovered from the gel were connected to the T vector and then sequenced and typed to obtain the genotype of this person: DPA1*01:03:01:05, DPA1*02:02:02:02, DPB1*02:01:19, DPB1:135:01, DQA1*02:01:01:02, DQA1*01:02:01:14, DQB1*02:01:08, DRA*01:02:01:01, DRA*01:01:01:05, DRB1*13:02:01:05, DRB4*01:03:02.

[0060] Example 4

[0061] The primers of the kit of this embodiment are selected as the second upstream primer set shown in Table 2 and the first downstream primer set shown in Table 1. The human cDNA gene sample provided in this embodiment is detected using the method of Example 1. The nucleic acid gel image is as follows: Figure 4 As shown, in this example, the fragments recovered from the gel were connected to the T vector and then sequenced and typed to obtain the genotype of this person as shown in Table 5.

[0062] Table 5 Genotyping results

[0063]

[0064] Example 5

[0065] The primers of the kit of this embodiment are selected as the second upstream primer set shown in Table 2 and the first downstream primer set shown in Table 1. The human cDNA gene sample provided in this embodiment is detected using the method of Example 1. The nucleic acid gel image is as follows: Figure 5 As shown, in this example, the fragments recovered from the gel were connected to the T vector and then sequenced and typed to obtain the genotype of this person as shown in Table 6.

[0066] Table 6 Genotyping results

[0067] 1 DQB1*03:01,DQB1*02:01 7 DQB1*03:01 2 DQB1*05:01 8 DQB1*03:03 3 DQB1*08:03,DQB1*09:01 9 DQB1*06:01,DQB1*03:01 4 DQB1*06:01,DQB1*03:01 10 DQB1*06:01 5 DQB1*05:01,DQB1*02:02 11 DQB1*02:01,DQB1*06:01 6 DQB1*05:01 12 DQB1*05:02,DQB1*02:02

[0068] Example 6

[0069] The primers of the kit of this embodiment are selected as the second upstream primer set shown in Table 2 and the first downstream primer set shown in Table 1. The human cDNA gene sample provided in this embodiment is detected using the method of Example 1. The nucleic acid gel image is as follows: Figure 6As shown, in this example, the fragments recovered from the gel were connected to the T vector and then sequenced and typed to obtain the genotype of this person as shown in Table 7.

[0070] Table 7 Genotyping results

[0071]

[0072] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention are within the scope of protection of the pending claims of the present invention. Sequence Listing <110> Nanjing University Institute of Artificial Intelligence and Biomedical Technology, Nanjing University <120> A sequencing and typing kit for MHCII CDS gene <160> twenty two <170> PatentIn version 3.5 <210> 1 <211> 20 <212> DNA <213> Artificial sequence <400> 1 atggccataa gtggagtccc 20 <210> 2 <211> 20 <212> DNA <213> Artificial sequence <400> 2 atggtgtgtc tgargctccc 20 <210> 3 <211> 20 <212> DNA <213> Artificial sequence <400> 3 atggtgtgtc tgaagctccc 20 <210> 4 <211> twenty one <212> DNA <213> Artificial sequence <400> 4 atgcgcccwg aagacagaat g 21 <210> 5 <211> twenty two <212> DNA <213> Artificial sequence <400> 5 atgatggttc tgcaggtttc tg 22 <210> 6 <211> twenty one <212> DNA <213> Artificial sequence <400> 6 atgatcctaa acaaagctct g 21 <210> 7 <211> twenty two <212> DNA <213> Artificial sequence <400> 7 atgtcttgga araagkcttt gc 22 <210> 8 <211> twenty one <212> DNA <213> Artificial sequence <400> 8 ttacagaggc cccctgcgtt c 21 <210> 9 <211> twenty one <212> DNA <213> Artificial sequence <400> 9 tcagctcagg aatcctsttg g 21 <210> 10 <211> twenty one <212> DNA <213> Artificial sequence <400> 10 tcagctcagg artcctgttg g 21 <210> 11 <211> 20 <212> DNA <213> Artificial sequence <400> 11 tcacagggkc ccctgggccc 20 <210> 12 <211> twenty one <212> DNA <213> Artificial sequence <400> 12 ttatgcagat cctcgytgaa c 21 <210> 13 <211> 20 <212> DNA <213> Artificial sequence <400> 13 tcacaakggc ccttggtgtc 20 <210> 14 <211> 19 <212> DNA <213> Artificial sequence <400> 14 tcagtgcagr agccctttc 19 <210> 15 <211> twenty four <212> DNA <213> Artificial sequence <400> 15 gctggggcca tcaaggcgga ccat 24 <210> 16 <211> twenty one <212> DNA <213> Artificial sequence <400> 16 agggccactc cagagaatta c 21 <210> 17 <211> 20 <212> DNA <213> Artificial sequence <400> 17 gaagrcattg tggctgacca 20 <210> 18 <211> twenty four <212> DNA <213> Artificial sequence <400> 18 agagacyctc ccgaggattt cgtg 24 <210> 19 <211> twenty four <212> DNA <213> Artificial sequence <400> 19 atcaaagaag aacatgtgat catc 24 <210> 20 <211> twenty one <212> DNA <213> Artificial sequence <400> 20 ggggacaccc raccacgttt c 21 <210> twenty one <211> twenty one <212> DNA <213> Artificial sequence <400> twenty one ggggacaccm gaccacgttt c 21 <210> twenty two <211> twenty four <212> DNA <213> Artificial sequence <400> twenty two ggggacaccc raccacgttt cttg 24

Claims

1. A sequencing typing kit for MHCII CDS gene, characterized in that: The kit comprises: PCR buffer, dNTPs, Taq enzyme and amplification primers, wherein the amplification primers consist of a first or second upstream primer set and a downstream primer set; The sequence of the first upstream primer set is shown in SEQ ID NO.1-7; the sequence of the second upstream primer set is shown in SEQ ID NO.15-22; the sequence of the downstream primer set is shown in SEQ ID NO.8-14; The method for using the kit comprises the following steps: 1) Extract sample cDNA; 2) performing PCR amplification on the cDNA; 3) Connecting the amplified product to a T vector and sequencing and typing; The amplification procedure of step 2) includes: pre-denaturation at 95°C for 3 minutes, denaturation at 92°C / 95°C for 15 seconds, annealing at 48-58°C for 15 seconds, extension at 72°C for 60 seconds, and complete extension at 72°C for 5 minutes; The denaturation, annealing and extension are performed sequentially once as one cycle, and the number of cycles is 4; The denaturation condition of the first cycle is 92°C; The annealing of the first to third cycles is repeated 3 times, and the annealing of the fourth cycle is repeated 25 times; The annealing temperature for amplifying HLA-DRA, HLA-DRB1, HLA-DRB345, HLA-DPA1, HLA-DPB1 and HLA-DQA1 was started from 58°C and decreased in 2°C increments during the cycle; The annealing temperature for amplifying HLA-DQB1 started from 54°C and decreased in increments of 2°C during the cycle.